<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="64231"><DrugName>copanlisib hydrochloride</DrugName><DrugNamesKey><Name id="43110561">Aliqopa</Name><Name id="42999337">copanlisib</Name><Name id="43058057">copanlisib hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>PI3K inhibitor (cancer), Bayer</Value></Name><Name><Value>BAY-80-6946</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>copanlisib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>copanlisib hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>Aliqopa</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>copanlisib dihydrochloride</Value></Name><Name><Value>1032568-63-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>1402152-13-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14455">Bayer AG</CompanyOriginator><CompaniesPrimary><Company id="14455">Bayer AG</Company></CompaniesPrimary><CrossReferences><SourceEntity id="64231" type="Drug"><TargetEntity id="675801" type="siDrug">Copanlisib hydrochloride</TargetEntity></SourceEntity><SourceEntity id="14455" type="Company"><TargetEntity id="4295869217" type="organizationId">Bayer AG</TargetEntity></SourceEntity><SourceEntity id="1734" type="ciIndication"><TargetEntity id="10008958" type="MEDDRA"/><TargetEntity id="690" type="siCondition"/></SourceEntity><SourceEntity id="1744" type="ciIndication"><TargetEntity id="C83.1" type="ICD10"/><TargetEntity id="10061275" type="MEDDRA"/><TargetEntity id="D020522" type="MeSH"/><TargetEntity id="52416" type="ORPHANET"/><TargetEntity id="-1332546842" type="omicsDisease"/><TargetEntity id="1384" type="siCondition"/></SourceEntity><SourceEntity id="1745" type="ciIndication"><TargetEntity id="C82" type="ICD10"/><TargetEntity id="D008224" type="MeSH"/><TargetEntity id="-1402578461" type="omicsDisease"/><TargetEntity id="1742" type="siCondition"/></SourceEntity><SourceEntity id="1746" type="ciIndication"><TargetEntity id="C88.4" type="ICD10"/><TargetEntity id="D018442" type="MeSH"/><TargetEntity id="-2003646849" type="omicsDisease"/><TargetEntity id="1743" type="siCondition"/></SourceEntity><SourceEntity id="1747" type="ciIndication"><TargetEntity id="10062113" type="MEDDRA"/><TargetEntity id="86854" type="ORPHANET"/><TargetEntity id="2002" type="siCondition"/></SourceEntity><SourceEntity id="1749" type="ciIndication"><TargetEntity id="C83.3" type="ICD10"/><TargetEntity id="10012818" type="MEDDRA"/><TargetEntity id="D016403" type="MeSH"/><TargetEntity id="544" type="ORPHANET"/><TargetEntity id="-308083648" type="omicsDisease"/><TargetEntity id="1741" type="siCondition"/></SourceEntity><SourceEntity id="1753" type="ciIndication"><TargetEntity id="C84.4" type="ICD10"/><TargetEntity id="10034623" type="MEDDRA"/><TargetEntity id="D016411" type="MeSH"/><TargetEntity id="-585182853" type="omicsDisease"/><TargetEntity id="3114" type="siCondition"/></SourceEntity><SourceEntity id="1765" type="ciIndication"><TargetEntity id="D018281" type="MeSH"/><TargetEntity id="70567" type="ORPHANET"/><TargetEntity id="-2122101383" type="omicsDisease"/><TargetEntity id="1844" type="siCondition"/></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"/><TargetEntity id="88673" type="ORPHANET"/><TargetEntity id="-1116061312" type="omicsDisease"/><TargetEntity id="1973" type="siCondition"/></SourceEntity><SourceEntity id="1772" type="ciIndication"><TargetEntity id="D012516" type="MeSH"/><TargetEntity id="668" type="ORPHANET"/><TargetEntity id="-100410430" type="omicsDisease"/><TargetEntity id="713" type="siCondition"/></SourceEntity><SourceEntity id="2448" type="ciIndication"><TargetEntity id="10039022" type="MEDDRA"/><TargetEntity id="D012208" type="MeSH"/><TargetEntity id="780" type="ORPHANET"/><TargetEntity id="-1229402267" type="omicsDisease"/><TargetEntity id="1343" type="siCondition"/></SourceEntity><SourceEntity id="2726" type="ciIndication"><TargetEntity id="10029260" type="MEDDRA"/><TargetEntity id="D009447" type="MeSH"/><TargetEntity id="635" type="ORPHANET"/><TargetEntity id="-2062438551" type="omicsDisease"/><TargetEntity id="712" type="siCondition"/></SourceEntity><SourceEntity id="2975" type="ciIndication"><TargetEntity id="10015560" type="MEDDRA"/><TargetEntity id="D012512" type="MeSH"/><TargetEntity id="319" type="ORPHANET"/><TargetEntity id="-1966079594" type="omicsDisease"/><TargetEntity id="1349" type="siCondition"/></SourceEntity><SourceEntity id="311" type="ciIndication"><TargetEntity id="10042971" type="MEDDRA"/><TargetEntity id="D016399" type="MeSH"/><TargetEntity id="-664594417" type="omicsDisease"/><TargetEntity id="704" type="siCondition"/></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"/><TargetEntity id="D008228" type="MeSH"/><TargetEntity id="547" type="ORPHANET"/><TargetEntity id="-1008757452" type="omicsDisease"/><TargetEntity id="703" type="siCondition"/></SourceEntity><SourceEntity id="3658" type="ciIndication"><TargetEntity id="10052358" type="MEDDRA"/><TargetEntity id="595" type="siCondition"/></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"/><TargetEntity id="613" type="siCondition"/></SourceEntity><SourceEntity id="3673" type="ciIndication"><TargetEntity id="5572" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1575" type="Action"><TargetEntity id="465" type="Mechanism">Phosphatidylinositol 3-Kinase (PI3K) Inhibitors</TargetEntity><TargetEntity id="3512" type="Mechanism">Inositol Phosphate Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01553" type="ciTarget"><TargetEntity id="59541" type="siTarget">Phosphatidylinositol 3-kinase (PI3K) (nonspecified subtype)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Follicle center lymphoma - US - Oct-2017</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1734">Chronic lymphocytic leukemia</Indication><Indication id="1745">Follicle center lymphoma</Indication><Indication id="1746">Marginal zone B-cell lymphoma</Indication><Indication id="1747">Splenic marginal zone lymphoma</Indication><Indication id="1753">Peripheral T-cell lymphoma</Indication><Indication id="1765">Cholangiocarcinoma</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="1772">Osteosarcoma</Indication><Indication id="2448">Rhabdomyosarcoma</Indication><Indication id="2726">Neuroblastoma</Indication><Indication id="2975">Ewing sarcoma</Indication><Indication id="311">T-cell lymphoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3658">Metastatic colorectal cancer</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="3673">Metastatic head and neck cancer</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="49">Breast tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1744">Mantle cell lymphoma</Indication><Indication id="1749">Diffuse large B-cell lymphoma</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="1575">Phosphoinositide 3-kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="1589">Apoptosis stimulator</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-30T10:16:50.000Z</LastModificationDate><ChangeDateLast>2019-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>2009-08-21T10:16:11.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14455" linkType="Company"&gt;Bayer&lt;/ulink&gt; has  developed and launched copanlisib (Aliqopa, BAY-80-6946), a pan class I PI3K inhibitor as copanlisib dihydrochloride salt. The product is indicated in the US for the treatment of adults with relapsed follicular lymphoma who have received at least two prior systemic therapies  [&lt;ulink linkID="1966806" linkType="Reference"&gt;1966806&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2017, copanlisib was granted accelerated approval in the US for  third-line follicular lymphoma [&lt;ulink linkID="1962532" linkType="Reference"&gt;1962532&lt;/ulink&gt;], [&lt;ulink linkID="1962389" linkType="Reference"&gt;1962389&lt;/ulink&gt;], [&lt;ulink linkID="1962328" linkType="Reference"&gt;1962328&lt;/ulink&gt;]; by October 2017, the drug had been launched in the US [&lt;ulink linkID="1975885" linkType="Reference"&gt;1975885&lt;/ulink&gt;]. In August 2015, a phase III trial (&lt;ulink linkID="222628" linkType="Protocol"&gt;&lt;/ulink&gt;CHRONOS-3) was initiated  in patients with relapsed indolent B-cell non-Hodgkin lymphoma (NHL) [&lt;ulink linkID="1636170" linkType="Reference"&gt;1636170&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development is ongoing in other cancer indications. In November 2012, a phase II trial (CHRONOS-1) was initiated  in indolent or aggressive NHL, including transformed indolent lymphoma, T-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma and marginal zone lymphoma (MZL)  [&lt;ulink linkID="1327182" linkType="Reference"&gt;1327182&lt;/ulink&gt;], [&lt;ulink linkID="1505625" linkType="Reference"&gt;1505625&lt;/ulink&gt;]. In April 2018, a phase I/II trial was initiated in pediatric patients with relapsed/refractory  solid tumors or lymphoma such as neuroblastoma, osteosarcoma, rhabdomyosarcoma and Ewing sarcoma [&lt;ulink linkID="2042712" linkType="Reference"&gt;2042712&lt;/ulink&gt;]. In October 2018, a phase I/II trial in combination with &lt;ulink linkID="54804" linkType="Drug"&gt;nivolumab&lt;/ulink&gt; in patients with advanced solid tumors including hepatocellular carcinoma, metastatic colorectal cancer, metastatic non-small-cell lung cancer (NSCLC), metastatic head and neck cancer was   initiated  [&lt;ulink linkID="2093622" linkType="Reference"&gt;2093622&lt;/ulink&gt;]. In July 2018, a phase I trial to assess copanlisib in combination of &lt;ulink linkID="89138" linkType="Drug"&gt;rogaratinib&lt;/ulink&gt; in patients with locally advanced or metastatic solid tumors was initiated [&lt;ulink linkID="2033296" linkType="Reference"&gt;2033296&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Investigator-led clinical trials in others cancer settings are ongoing, listing Bayer as collaborator. In June 2016, a phase II trial for cholangiocarcinoma was initiated [&lt;ulink linkID="1906962" linkType="Reference"&gt;1906962&lt;/ulink&gt;]. In August 2017 a phase I/II trial was initiated in  patients with hormone receptor positive HER2 negative stage I-IV breast cancer [&lt;ulink linkID="1925083" linkType="Reference"&gt;1925083&lt;/ulink&gt;]. In February 2018, an investigator-led phase I/II trial for peripheral T-cell lymphoma was initiated [&lt;ulink linkID="1900871" linkType="Reference"&gt;1900871&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Bayer was developing the drug for the potential treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) [&lt;ulink linkID="1327182" linkType="Reference"&gt;1327182&lt;/ulink&gt;], [&lt;ulink linkID="1955280" linkType="Reference"&gt;1955280&lt;/ulink&gt;]. In November 2012, a phase II trial was initiated in DLBCL [&lt;ulink linkID="1327182" linkType="Reference"&gt;1327182&lt;/ulink&gt;];  however, by March 2018 further development for this indication was not planned [&lt;ulink linkID="2031285" linkType="Reference"&gt;2031285&lt;/ulink&gt;]. In September 2015, a phase IIa trial in MCL was initiated; however, in January 2017, this trial was terminated  [&lt;ulink linkID="1955280" linkType="Reference"&gt;1955280&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The drug has patent coverage until at least March 2032 in Europe and Japan [&lt;ulink linkID="PA7663288" linkType="Patent"&gt;EP-02694508&lt;/ulink&gt;], [&lt;ulink linkID="PA7752982" linkType="Patent"&gt;JP-05763834&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;By April 2017, Bayer had initiated a rolling submission with the FDA for the third-line treatment of  follicular lymphoma [&lt;ulink linkID="1922811" linkType="Reference"&gt;1922811&lt;/ulink&gt;], [&lt;ulink linkID="1922820" linkType="Reference"&gt;1922820&lt;/ulink&gt;]. In May 2017, the FDA granted Priority Review     [&lt;ulink linkID="1928196" linkType="Reference"&gt;1928196&lt;/ulink&gt;]; in September 2017, accelerated approval was granted based on data from the phase II CHRONOS-1 study [&lt;ulink linkID="1962532" linkType="Reference"&gt;1962532&lt;/ulink&gt;], [&lt;ulink linkID="1962389" linkType="Reference"&gt;1962389&lt;/ulink&gt;], [&lt;ulink linkID="1962328" linkType="Reference"&gt;1962328&lt;/ulink&gt;]. By October 2017, the drug had been launched in the US [&lt;ulink linkID="1975885" linkType="Reference"&gt;1975885&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2015, the FDA granted Orphan designation for follicular lymphoma [&lt;ulink linkID="1631964" linkType="Reference"&gt;1631964&lt;/ulink&gt;]. In February 2017, the FDA granted Orphan designation for splenic marginal zone lymphoma, extranodal marginal zone lymphoma, and nodal marginal zone lymphoma [&lt;ulink linkID="1899225" linkType="Reference"&gt;1899225&lt;/ulink&gt;], [&lt;ulink linkID="1899227" linkType="Reference"&gt;1899227&lt;/ulink&gt;], [&lt;ulink linkID="1899229" linkType="Reference"&gt;1899229&lt;/ulink&gt;]. In May 2019, the US FDA granted Breakthrough Therapy designation  for the treatment of adult patients with relapsed marginal zone lymphoma who have received at least two prior therapies [&lt;ulink linkID="2156883" linkType="Reference"&gt;2156883&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In July 2018, the COMP of the EMA recommended granting copanlisib Orphan designation for treatment of marginal zone lymphoma [&lt;ulink linkID="2059302" linkType="Reference"&gt;2059302&lt;/ulink&gt;]; in August 2018, the Orphan designation was granted [&lt;ulink linkID="2079561" linkType="Reference"&gt;2079561&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;By October 2017, copanlisib hydrochloride was listed in phase III development in Japan [&lt;ulink linkID="1975885" linkType="Reference"&gt;1975885&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, a randomized, double-blind, placebo-controlled, phase III (&lt;ulink linkID="248251" linkType="Protocol"&gt;NCT02626455&lt;/ulink&gt;; 17833; 2015-001088-38; CHRONOS-4) study to evaluate the efficacy of copanlisib in combination with rituximab and bendamustine or rituximab and CHOP in patients (expected n = 676) with relapsed B-cell indolent NHL in the US, Australia, Europe, Asia, Israel and Turkey.  At that time, the trial was expected to complete  in December 2024 [&lt;ulink linkID="1755605" linkType="Reference"&gt;1755605&lt;/ulink&gt;]. The primary endpoints were PFS and determination of the recommended phase III dose of copanlisib (safety run-in phase only), and secondary endpoints were objective response rate, duration of response, time to progression, complete response rate, OS, time to deterioration, time to improvement in disease-related symptoms, safety and tolerability, and time to next anti-lymphoma treatment. Recruitment began in January 2016 across study sites in the US, South America, Europe and Asia. The primary results were to be expected in 2021 [&lt;ulink linkID="1960380" linkType="Reference"&gt;1960380&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2015, a randomized, parallel assignment, placebo-controlled, double-blind, safety/efficacy, phase III study (&lt;ulink linkID="222628" linkType="Protocol"&gt;NCT02369016&lt;/ulink&gt;; 17322, 2014-000925-19; CHRONOS-2) was initiated in the US, South America, Europe, Asia, Mexico, Saudi Arabia and South Africa in patients with rituximab-refractory indolent NHL (expected n = 189). At that time, the study was expected to complete in October 2019. In September 2017, the trial was expected to complete in May 2018 [&lt;ulink linkID="1638818" linkType="Reference"&gt;1638818&lt;/ulink&gt;]. In February 2019, the trial was expected to complete in December 2019; at that time, the trial was no longer recruiting, and  25 participants had been enrolled in Brazil, Europe, China, South Korea, South Africa, Taiwan and Turkey [&lt;ulink linkID="1638818" linkType="Reference"&gt;1638818&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, a randomized, double-blind, placebo-controlled, parallel assignment, phase III trial (&lt;ulink linkID="222423" linkType="Protocol"&gt;NCT02367040&lt;/ulink&gt;; 17067, 2013-003893-29; CHRONOS-3)  was initiated in the US, Australia,  Europe,  Turkey, the Far East and Argentina in patients (expected n = 514) with   relapsed indolent B-cell NHL to assess the safety and efficacy of  copanlisib in combination with &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt;. At that time, the trial was expected to complete in December 2020 [&lt;ulink linkID="1636170" linkType="Reference"&gt;1636170&lt;/ulink&gt;], [&lt;ulink linkID="1650307" linkType="Reference"&gt;1650307&lt;/ulink&gt;]. The primary endpoint was PFS, and secondary endpoints were objective response rate, duration of response, time to progression, complete response rate, overall survival (OS), time to deterioration, time to improvement in disease-related symptoms, safety and tolerability. Recruitment began in August 2015 across approximately 100 sites in the US, South America, Europe and the Far East. The primary results were to be expected in 2019 [&lt;ulink linkID="1960380" linkType="Reference"&gt;1960380&lt;/ulink&gt;]. By February 2019, the trial was also recruiting in Japan, Mexico, South Korea, New Zealand, South Africa, Singapore and Thailand; at that time, the trial was planned to complete in August 2020 [&lt;ulink linkID="1636170" linkType="Reference"&gt;1636170&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In October 2018, a non-randomized, sequential assignment, open-label, multi-center, phase I/II trial (&lt;ulink linkID="359275" linkType="Protocol"&gt;NCT03735628&lt;/ulink&gt;; 19769) to evaluate the safety and efficacy of copanlisib in combination with nivolumab in patients (expected n = 160) with advanced solid tumors including hepatocellular carcinoma, metastatic colorectal cancer, metastatic non small cell lung cancer, metastatic head and neck cancer was to be initiated 'later that month'. At that time, the trial was expected to complete in April, 2021. Later that month, the trial was initiated in the US and Canada [&lt;ulink linkID="2093622" linkType="Reference"&gt;2093622&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, a non-randomized, open-label, dose-escalation, multicenter, phase I/II trial (&lt;ulink linkID="331813" linkType="Protocol"&gt;NCT03458728&lt;/ulink&gt;; 19176; 2017-000383-15) was initiated in the US to evaluate the safety, tolerability and pharmacokinetics of the drug in pediatric patients (expected n = 130) with relapsed/refractory  solid tumors or lymphoma such as neuroblastoma, osteosarcoma, rhabdomyosarcoma and Ewing sarcoma. At that time, the trial was expected to complete in August  2021 [&lt;ulink linkID="2042712" linkType="Reference"&gt;2042712&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, an investigator-led randomized, parallel assignment, phase I/II trial (&lt;ulink linkID="296462" linkType="Protocol"&gt;NCT03128619&lt;/ulink&gt;; 16-001271; NCI-2017-00435; 16-001271), in which Bayer was listed as collaborator, to evaluate the safety of copanlisib, letrozole, and palbociclib in the phase I portion of the trial in metastatic breast cancer and to compare the molecular effects of neoadjuvant copanlisib in combination with palbociclib and letrozole versus copanlisib + letrozole versus palbociclib + letrozole in the phase II portion of the trial in patients with hormone receptor positive HER2 normal breast cancer was planned to be initiated in May 2017. At that time, the trial was expected to complete in May 2021 [&lt;ulink linkID="1925083" linkType="Reference"&gt;1925083&lt;/ulink&gt;]. In August 2017, the trial was initiated [&lt;ulink linkID="1925083" linkType="Reference"&gt;1925083&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2017, an investigator-led open-label, single-group assigned, prospective, multicenter, phase I/II trial (&lt;ulink linkID="288180" linkType="Protocol"&gt;NCT03052933&lt;/ulink&gt;, COPGEM), in which Bayer was listed as collaborator, to evaluate the efficacy and safety of copanlisib and gemcitabine combination in patients (expected n = 36) with relapsed/refractory peripheral T-cell or NK/T-cell lymphoma was planned to be initiated in South Korea in May 2017. At that time, the trial was expected to be completed in December 2021 [&lt;ulink linkID="1900871" linkType="Reference"&gt;1900871&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, an investigator-led single-group assignment, interventional, phase II trial (&lt;ulink linkID="248938" linkType="Protocol"&gt;NCT02631590&lt;/ulink&gt;; MCC-18435), in which Bayer was listed as collaborator, to evaluate copanlisib in combination with gemcitabine and cisplatin for the treatment of patients (expected n = 25) with advanced cholangiocarcinoma was initiated in the US. At that time, the trial was expected to complete in December 2020 [&lt;ulink linkID="1906962" linkType="Reference"&gt;1906962&lt;/ulink&gt;]. The primary objective of the study was progression free survival (PFS) at 6 months with secondary objectives being response rate, median PFS, overall survival, safety and tolerability. At that time, 11 patients had been enrolled [&lt;ulink linkID="2000670" linkType="Reference"&gt;2000670&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, a single-arm, open-label, phase IIa trial (&lt;ulink linkID="230538" linkType="Protocol"&gt;NCT02455297&lt;/ulink&gt;; 17120) was initiated in the US to assess the efficacy and safety of copanlisib monotherapy in patients (expected n = 12) with relapsed or refractory mantle cell lymphoma (MCL), who failed ibrutinib treatment or were unable to tolerate ibrutinib. The primary endpoint was objective response rate with a time frame of 24 weeks. In December 2016, the trial completed having accrued four patients, and the trial was subsequently terminated in January 2017 [&lt;ulink linkID="1955280" linkType="Reference"&gt;1955280&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, an open-label, single-arm, phase II study (&lt;ulink linkID="226848" linkType="Protocol"&gt;NCT02391116&lt;/ulink&gt;; 17119; 2014-004848-36) began in Australia, Canada, Europe, Asia and Turkey  in patients (n = 67) with relapsed or refractory DLBCL.  The trial was expected to complete in January 2018 [&lt;ulink linkID="1650369" linkType="Reference"&gt;1650369&lt;/ulink&gt;], [&lt;ulink linkID="1650307" linkType="Reference"&gt;1650307&lt;/ulink&gt;]. In June 2017, clinical data were presented at the 53rd ASCO meeting in Chicago, IL. In per protocol set of 40 patients (16, 22 and 2 with ABC like DLBCL, germinal center B-cell (GCB) like DLBCL and unclassified subtype, respectively), objective response rate (ORR; primary endpoint) was 25%; complete and partial response was achived by 5 patients each, and stable disease was observed in 12 patients. In full analysis set, ORR was 19.4%; complete and partial response was achieved by five and eight patients, respectively.  In per protocol set, median duration of response was 113 days, median PFS was 84 days. In full analysis set, median overall survival was 224 days [&lt;ulink linkID="1932212" linkType="Reference"&gt;1932212&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, an open-label, single group assignment, uncontrolled, phase I/II b study (&lt;ulink linkID="220374" linkType="Protocol"&gt;NCT02342665&lt;/ulink&gt;; 17792) was initiated  to assess the   safety and efficacy of the drug in Japanese patients (expected n  = 26) with  indolent B-cell NHL relapsed after or refractory to standard therapy. At that time, the study was expected to complete in March 2019  [&lt;ulink linkID="1629724" linkType="Reference"&gt;1629724&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2012, a non-randomized, open-label, phase II study (&lt;ulink linkID="90005" linkType="Protocol"&gt;NCT01660451&lt;/ulink&gt;; 6349  2012-002602-52; CHRONOS-1) was initiated  to evaluate the efficacy and safety of copanlisib (0.8 mg/kg dosed weekly for 3 weeks with a 1-week interval) in previously treated patients (expected n = 60) with indolent or aggressive NHL in the US, Canada and Europe. The primary endpoint was tumor response up to 10 months [&lt;ulink linkID="1327182" linkType="Reference"&gt;1327182&lt;/ulink&gt;]. In December 2013, preliminary data were presented at the 55th ASH Meeting in New Orleans, LA. The objective response rates (primary endpoint) were 13, 17, 50, 71, 40, 43 and 66% among patients with diffuse large B-cell lymphoma, transformed indolent lymphoma, T-cell lymphoma, MCL, follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma and marginal zone lymphoma, respectively [&lt;ulink linkID="1505625" linkType="Reference"&gt;1505625&lt;/ulink&gt;]. In November 2014, clinical data were presented from an open-label, uncontrolled, phase IIa study for the potential treatment of relapsed/refractory, indolent or aggressive lymphoma in 67 patients at the 26th EORTC-NCI-AACR Symposium in Barcelona, Spain.													Copanlisib (0.8 mg/kg iv; maximum dose 65 mg) on days I, 8 and 15 of a 28-day cycle. Complete responses/unconfirmed complete response were reported in follicular lymphoma, MCL and peripheral T-cell lymphoma. In the indolent cohort and aggressive cohort, overall response rates,  progression free survival, median times to responses were achieved.  Hyperglycemia (62.7%), hypertension (61.2%), fatigue (44.8%) and diarrhea (40.3%) were most common treatment emergent adverse events [&lt;ulink linkID="1613549" linkType="Reference"&gt;1613549&lt;/ulink&gt;]. In December 2014, similar clinical data were presented at the 56th ASH Meeting in San Francisco, CA							[&lt;ulink linkID="1617709" linkType="Reference"&gt;1617709&lt;/ulink&gt;]. In March 2015, the trial was expected to complete in the first half of 2016 [&lt;ulink linkID="1641034" linkType="Reference"&gt;1641034&lt;/ulink&gt;]. In April 2015, data from the expansion phase or part B of the trial were presented at the 106th AACR meeting in Philadelphia, PA. Post-infusion, transient increases in blood glucose and BP were observed and copanlisib demonstrated promising efficacy as a single agent in heavily pretreated patients with indolent non-Hodgkin's lymphoma. Part B or expansion trial was initiated in April 2014. At that time, results were expected in 2016 [&lt;ulink linkID="1649650" linkType="Reference"&gt;1649650&lt;/ulink&gt;]. In December 2015, final data for the subset of patients with MCL (n = 11) were presented at the 57th ASH Annual Meeting and Exposition in Orlando, FL. The objective response rate was 63.6% including unconfirmed complete responses (18.2%) and partial responses (45.5%). Median progression-free survival and overall survival was 112 and 445 days, respectively. Copanlisib demonstrated a manageable safety profile [&lt;ulink linkID="1718508" linkType="Reference"&gt;1718508&lt;/ulink&gt;]. In June 2016, results were presented at the 52nd ASCO meeting in Chicago, IL. Patients with high BCR and PI3K weighted gene expression score (WGS) compared with those with low BCR and PI3K WGS had increased response rates. Progression-free survival was longer in copanlisib-treated patients with high (above the median) BCR (377 and 62 days, respectively) and PI3K (288 and 104 days, respectively) WGS compared with those with low BCR and PI3K WGS [&lt;ulink linkID="1770018" linkType="Reference"&gt;1770018&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 21st EHA Annual Meeting in Copenhagen, Denmark. Overall, response rates were increased in patients with high BCR and PI3K weighted gene expression score compared to low (AUC = 0.81 and 0.75, respectively) [&lt;ulink linkID="1771360" linkType="Reference"&gt;1771360&lt;/ulink&gt;]. Further data were presented at the same conference. In the indolent and aggressive cohorts, 14 and 13 patients achieved an objective response, respectively, and resulted in overall response rate of 44 and 27%, respectively. Complete response, partial response, stable disease and progressive disease were observed in 4, 20, 26 and 10 patients, respectively. In indolent and aggressive cohorts, median duration for response was 390 and 166 days, respectively and time to response was 52 and 51 days, respectively, median progression free survival (PFS) was 294 and 70 days, respectively [&lt;ulink linkID="1771047" linkType="Reference"&gt;1771047&lt;/ulink&gt;]. In April 2017, further primary results from part B study in 141 patients with relapsed or refractory indolent B-cell lymphoma were presented at the 108th AACR Annual Meeting in Washington DC. The objective tumor response rate  was 59.2% (12% complete response and 47.2% partial response. Stable disease and progressive disease were observed in 29.6 and 2.1%, respectively. The KM-estimate of median progression-free survival was found to be 340 days. At that time, median overall survival was not yet been reached.  The most commonly reported treatment-related adverse events (all grade/grade 3+) were hyperglycemia (49/40%) and hypertension (29/23%) [&lt;ulink linkID="1913968" linkType="Reference"&gt;1913968&lt;/ulink&gt;], [&lt;ulink linkID="1913384" linkType="Reference"&gt;1913384&lt;/ulink&gt;]. In June 2017, further clinical data were presented at the 53rd ASCO meeting in Chicago, IL. Copanlisib treatment demonstrated favorable impact on disease-related symptoms and health-related quality of life in patients with relapsed/refractory indolent NHL [&lt;ulink linkID="1940319" linkType="Reference"&gt;1940319&lt;/ulink&gt;]. Further data of 104 patients with follicular lymphoma were presented from the same conference. CR was achieved by 15 patients, partial response was archived by 46 patients, stable disease was observed in 34 patients, unconfirmed stable disease was observed in 1 patient, progressive disease was observed in 2 patients, objective response rate was 58.7%. Of 5 grade 5 events, three (lung infection, respiratory failure and thromboemobolic event) were drug related [&lt;ulink linkID="1932023" linkType="Reference"&gt;1932023&lt;/ulink&gt;]. Later that month, further data were presented at the 22nd EHA Annual Congress in Madrid, Spain. Patients who had some degree of tumor shrinkage as best response and &amp;gt;50% tumor shrinkage were 91 and 60%, respectively, as per investigator assessment. Deaths reported were six, three of which were attributed to copanlisib (one lung infection, one respiratory failure, and one thromboembolic event) [&lt;ulink linkID="1939458" linkType="Reference"&gt;1939458&lt;/ulink&gt;]. In December 2017, further data were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. In overall patients (n = 142), complete response, partial response, stable disease, unconfirmed stable disease, and progressive disease was observed in 20, 63, 44, 1, and 3 patients, respectively. Objective response rate was observed in 83 patients as of the February 2017 cut off when compared with 84 patients in the June 2016 dataset [&lt;ulink linkID="1988597" linkType="Reference"&gt;1988597&lt;/ulink&gt;]. Further data were presented at the same conference. Of 15 patients with nodal disease, 12 patients had objective tumor response, and of 4 patients with MALT lymphoma, 1 patient achieved response. At data cut-off, the median duration of response was not reached. At data cut-off, reduction in target lesion from baseline was achieved by 17 patients, of which at least 50% reduction was achieved by 14 patients. Hyperglycemia, hypertension, lung infection, decreased neutrophil count, decreased platelet count and diarrhea were the most commonly reported grade 3 TEAEs. In MZL subset, treatment-related death or fatal opportunistic infections did not occur. Increased ALT and AST were the safety laboratory toxicities of interest which were reported by 24.1 and 30.5% for all grade, 20.6 and 27.0% of patients for grade 1, and each 3.5% of patients for grade &amp;gt;/= 2, respectively [&lt;ulink linkID="1988583" linkType="Reference"&gt;1988583&lt;/ulink&gt;], [&lt;ulink linkID="1989556" linkType="Reference"&gt;1989556&lt;/ulink&gt;]. In June 2018, further data were presented at the 23rd EHA Annual Congress in Stockholm, Sweden.  In June 2018, further data were presented at the 23rd EHA Annual Congress in Stockholm, Sweden. In overall, diabetic and non-diabetic patients, the objective repose rate was 84, 45, 61.5% with complete response of 12, 5 and 13.1%, partial response of 47.2, 40, 48.4%; stable disease of 29.6, 35, 28.7%, progressive disease of 2.1, 5 and 1.6%, respectively and disease control rate was 85.9, 75 and 87.7%, respectively. Overall, 95 and 99.2% of diabetic and non diabetic patients had any grade TEAEs, respectively. Hyperglycemia events were generally transient and infusion-related in both diabetic and non diabetic patients  [&lt;ulink linkID="2045650" linkType="Reference"&gt;2045650&lt;/ulink&gt;]. In June 2018, further data were presented at the 54th ASCO Annual Meeting in Chicago, IL. The most commonly reported TEAEs of grade 4 severity was hyperglycemia (35%) in diabetic patient; and neutropenia (14.8%) in non-diabetic patient. Of six who had experienced dose reductions due to hyperglycemia, four patients achieved a CR or PR, two of whom remained on treatment for approximately two years [&lt;ulink linkID="2040081" linkType="Reference"&gt;2040081&lt;/ulink&gt;]. In December 2018, further clinical data were presented at the 60th ASH Annual Meeting and Exposition in San Diego, CA. Complete response, partial response, objective response, stable disease and progressive disease was observed in 17.2, 40.9, 58.1, 28 and 1.1% (progression of disease (POD) &amp;lt; 24); 17, 51.1, 68.1, 25.5 and 4.3% (POD &amp;gt; 24), respectively. The median progression free survival was 11.3 and 17.6 months in POD &amp;lt; 25 and &amp;gt; 24, respectively, whereas median overall survival was 42.6 and not reached in in POD &amp;lt; 25 and &amp;gt; 24, respectively. Serious adverse events were reported in 29.3% [&lt;ulink linkID="2098239" linkType="Reference"&gt;2098239&lt;/ulink&gt;]. Further clinical data were presented at the same conference. Objective responses were observed in 60.6% and overall response rate was observed in &amp;gt; 60% in all subsets. Complete response, partial response, stable disease, progressive disease, overall response rate and disease control rate was observed in 10, 30, 40, 5, 40 and 75% (diabetes patients); 18, 45.9, 26.2, 1.6, 63.9 and 87.7% (no diabetes patients); 26.8, 34.1, 24,4, 4.9, 61 and 82.9% (hypertension); 12.9, 47.5, 29.7, 1, 60.4 and 87.1% (no hypertension), respectively. Any treatment emergent adverse events (TEAE), grade-3, grade-4 and grade-5 TEAE were reported in 95, 40, 45 and 10% (diabetic); 99.2, 56.6, 26.2 and 3.3% (non-diabetic); 97.6, 63.4, 19.5 and 7.3% (hypertension); 99, 50.5, 32.7 and 3% (no hypertension), respectively [&lt;ulink linkID="2098558" linkType="Reference"&gt;2098558&lt;/ulink&gt;]. Further clinical data were presented at the same conference. Complete response, partial response, stable disease, progressive disease, overall response rate and disease control rate was observed in 20.2, 38.5, 33.7, 1.9, 58.7 and 87.5% (follicular lymphoma); 13, 65.2, 8.7, 0, 78.3 and 87% (marginal cell lymphoma); 0, 75, 12.5, 12.5, 0, 75 and 87.5% (small lymphocytic lymphoma); 0, 16.7, 50, 0, 16.7 and 66.7% (Waldenstorm macroglobulinemia/ Lymphoplasmacytic lymphoma), respectively [&lt;ulink linkID="2098257" linkType="Reference"&gt;2098257&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;June 2018, phase Ib data from an open-label, single arm adaptive, multicenter, phase Ib/II study (&lt;ulink linkID="255521" linkType="Protocol"&gt;NCT02705859&lt;/ulink&gt;; PantHER) which evaluated the efficacy and safety of copanlisib and &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; combination in patients (n = 12) with  recurrent or metastatic HER2-positive breast cancer were presented at the 54th ASCO Annual meeting in Chicago, IL. Fatigue, hyperglycemia, hypertension, nausea and vomiting were the most commonly treatment-related adverse events (all grades) reported in &amp;gt; 2 patients. Grade 3 serious adverse events were lung infection and abdominal pain and were considered possibly related to copanlisib; all others were considered unlikely or not related to copanlisib. DLTs were not reported at either dose level. The recommended phase II dose for the combination of copanlisib and trastuzumab was found to be 60 mg. Disease control rate was 75%; stable disease and progressive disease were observed in nine and three patients, respectively. At that time, phase II part of this study was open and the target accrual was 19 patients [&lt;ulink linkID="2039939" linkType="Reference"&gt;2039939&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2018, results were presented from a study (&lt;ulink linkID="212225" linkType="Protocol"&gt;NCT02253420&lt;/ulink&gt;) evaluating the effects of rifampin on the pharmacokinetics of copanlisib in patients with advanced solid tumors was presented at the 54th ASCO Annual Meeting in Chicago, IL. Patients (n = 12) received copanlisib 60 mg (iv) on cycle 1 day 1 (C1D1) and 15 and rifampin 600 mg (po, qd) on from C1D10 to C1D21 for 12 days. With coadministration of rifampin, copanlisib clearance increased by 2.3-fold from 22.6 to 51.4 L/h. Coadministration of rifampin for 12 days with a single iv dose of copanlisib, the geometric LS mean for Cmax was 0.857, AUC(0 to 168) was 0.459 and AUC was 0.439 when compared to copanlisib alone [&lt;ulink linkID="2044306" linkType="Reference"&gt;2044306&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2018, single-group-assignment, open-label phase I trial (&lt;ulink linkID="338906" linkType="Protocol"&gt;NCT03517956&lt;/ulink&gt;; 2018-000419-26; 19774; ROCOCO) was expected to begin in Germany in September 2018 to assess a combination of &lt;ulink linkID="89138" linkType="Drug"&gt;rogaratinib&lt;/ulink&gt; and copanlisib in patients (expected n = 65) with FGFR-positive, locally advanced or metastatic solid tumors. The primary endpoints were related to adverse events. At that time, the trial was expected to complete in April 2021 [&lt;ulink linkID="2033296" linkType="Reference"&gt;2033296&lt;/ulink&gt;]. In July 2018, the trial was initiated in the US, Europe, South Korea and Singapore [&lt;ulink linkID="2033296" linkType="Reference"&gt;2033296&lt;/ulink&gt;]. In August 2018, the trial was expected to complete in March 2021 [&lt;ulink linkID="2033296" linkType="Reference"&gt;2033296&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2018, an open-label, single-group-assignment, phase I trial (&lt;ulink linkID="336232" linkType="Protocol"&gt;NCT03498430&lt;/ulink&gt;; 16866) was planned to determine the pharmacokinetics of &lt;ulink linkID="64231" linkType="Drug"&gt;&lt;/ulink&gt;copanlisib in      Chinese patients (expected n = 12) with relapsed indolent non-Hodgkin's lymphoma (iNHL). At that time, the estimated primary completion date was June 2019 [&lt;ulink linkID="2030138" linkType="Reference"&gt;2030138&lt;/ulink&gt;]. Later that month, the trial was initiated [&lt;ulink linkID="2030138" linkType="Reference"&gt;2030138&lt;/ulink&gt;]. In February 2019, the trial was expected to complete in April 2020 [&lt;ulink linkID="2030138" linkType="Reference"&gt;2030138&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, data from an open-label, single-arm, phase I study (&lt;ulink linkID="193917" linkType="Protocol"&gt;NCT02155582&lt;/ulink&gt;) were presented in 63 non-Hodgkin's lymphoma and advanced solid tumor patients at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. Patients (n = 63) received copanlisib (0.8 or 0.4 mg/kg) as a 1 h- iv infusion on days 1, 8 and 15 for the first 3 weeks of a 28-day cycle, followed by 1 week off. Diabetic patients received either 45 or 60 mg. Following the first copanlisib infusion, dose-dependent, transient and reversible increases in mean plasma glucose and mean systolic BP. Cmax and AUC exposure increased dose-proportionally following infusion of copanlisib from 0.4 to 0.8 mg/kg. In the lymphoma cohorts (n = 33), complete response was observed in two patients (one with peripheral T-cell lymphoma and one with DLBCL, both receiving 0.8 mg/kg dose). Partial response was achieved by five patients (four at the 0.8 mg/kg dose and one at 0.4 mg/kg dose). Stable disease and disease progression were observed in 5 and 12 patients, respectively.  Among patients with solid tumors, one achieved partial response, 13 had stable disease and 14 had disease progression. Overall, TEAEs of any grade were reported in 93.7% of patients [&lt;ulink linkID="1988566" linkType="Reference"&gt;1988566&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;In March 2016, clinical data from a single-center, open-label, non-randomized, non-controlled first-in-man study (&lt;ulink linkID="183109" linkType="Protocol"&gt;NCT02119221&lt;/ulink&gt;) which evaluated the safety and pharmacokinetics of a single iv dose of copanlisib (BAY-80-6946) in 18 healthy subjects were presented at the 117th ASCPT Annual Meeting in San Diego, CA. Of 18 subjects, 6 received copanlisib (12 mg, 1-h iv infusion) with 2.66 MBq [11C]copanlisib.   Geometric mean values of Cmax, AUC, t1/2, total body clearance, MRT, Vd, and median time was 44.1 microg/l, 442 microg.h/l, 52.1 h, 24.8 l/h, 62.7 h, 1870 l and 0.967 h, respectively.  Overall, copanlisib was well tolerated [&lt;ulink linkID="1743438" linkType="Reference"&gt;1743438&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, data from a multicenter, open-label phase Ib study of copanlisib in combination with &lt;ulink linkID="56559" linkType="Drug"&gt;refametinib&lt;/ulink&gt; performed in 64 advanced cancer patients were presented at the 50th ASCO meeting in Chicago, IL.Pharmacokinetic exposures were not affected with combination therapy. Overall, one patient had minor response [&lt;ulink linkID="1562817" linkType="Reference"&gt;1562817&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013,  data from a phase I study were presented at the 104th AACR Meeting in Washington DC. In the   safety, tolerability and pharmacokinetic study, Japanese subjects (n = 10) with advanced or refractory solid tumors received 0.4 and 0.8 mg/kg doses of BAY-80-6946 as 1 h iv infusions. DLTs were not observed in either of the cohorts. The gastrointestinal stromal tumor patient previously on &lt;ulink linkID="11460" linkType="Drug"&gt;imatinib&lt;/ulink&gt; and &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt; treatment had stable disease at the end of 5th cycle  but discontinued BAY-80-6946 treatment due to drug-related thrombocytopenia. BAY-80-6946 demonstrated an approximately dose-proportional AUC values. The AUC for BAY-80-6946 did not accumulate between day 1 and day 15. BAY-80-6946 had an t1/2 of approximately 32 to 36 h after cycle 1 day1 dose. BAY-80-6946 was well tolerated with an MTD of 0.8 mg/kg [&lt;ulink linkID="1399927" linkType="Reference"&gt;1399927&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, a non-randomized, open-label, phase I study (&lt;ulink linkID="81893" linkType="Protocol"&gt;NCT01460537&lt;/ulink&gt;; 12875) was initiated in patients with advanced solid tumors (expected n = 60) in the US, to assess the safety, pharmacokinetics and pharmacodynamics of copanlisib in combination with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; or gemcitabine plus cisplatin. At that time, the study was scheduled to complete in September 2013 [&lt;ulink linkID="1237047" linkType="Reference"&gt;1237047&lt;/ulink&gt;].  In June 2014, further data were presented at the 50th ASCO meeting in Chicago, IL.  In group B, one patient showed complete response and one patient showed partial response. Partial response was seen in two biliary tract cancer patients in expansion cohort and stable disease was seen in two patients [&lt;ulink linkID="1562117" linkType="Reference"&gt;1562117&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2009, the agent was listed as being in phase I development [&lt;ulink linkID="978349" linkType="Reference"&gt;978349&lt;/ulink&gt;]. In August 2009, a phase I, open-label, dose-escalation, safety study (&lt;ulink linkID="59742" linkType="Protocol"&gt;NCT00962611&lt;/ulink&gt;; 12871) was planned in the US in patients (expected n = 60) with advanced cancer. Copanlisib would be given in a weekly 1-h  iv infusion  for 3 weeks  followed by a 1-week break, until disease progression or development of toxicities. The primary outcome would characterize safety, tolerability and pharmacokinetics, determine the maximum tolerated dose, and evaluate biomarkers. The study was expected to begin in September 2009 and finish in January 2012 [&lt;ulink linkID="1035881" linkType="Reference"&gt;1035881&lt;/ulink&gt;]. By April 2010, the phase I trial was underway [&lt;ulink linkID="1035881" linkType="Reference"&gt;1035881&lt;/ulink&gt;], [&lt;ulink linkID="1089515" linkType="Reference"&gt;1089515&lt;/ulink&gt;]. In June 2011,  data were presented at the 47th ASCO meeting in Chicago, IL. The MTD was determined to be 0.8 mg/kg. Increases in fasting insulin and fasting glucose were observed at doses &amp;gt;/= 0.2 and &amp;gt;/=0.4 mg/kg, respectively. The degree of hyperglycemia was dose-related and was at least grade 2 in all subjects at the MTD; however, hyperglycemia peaked 5 to 8 h after the start of infusion and was resolved within 2 to 3 days.  At 48 h post   dose, a &amp;gt;/=30% decrease in maximum SUV was observed for lesions in two of the five subjects treated at the MTD [&lt;ulink linkID="1195471" linkType="Reference"&gt;1195471&lt;/ulink&gt;]. In March 2012, further data were presented at TAT 2012 in Amsterdam, the Netherlands. A partial response was observed in patients with breast cancer and follicular non-Hodgkin's lymphoma and a half-life of 38 h was determined. A DLT of grade 4 left ventricular dysfunction occurred at a dose of 1.2 mg/kg [&lt;ulink linkID="1273194" linkType="Reference"&gt;1273194&lt;/ulink&gt;]. In December 2012, further data from MTD dose-expansion cohort were presented at the 54th ASH Annual meeting in Atlanta, GA. The Cmax and AUC values of copanlisib were 507 microg/l, and 1752 microg.h/l, respectively, at day 15, and the average half-life was 41 h. Partial response (PR) was achieved by all follicular lymphoma patients, with maximum duration of response as high as 596 days. Of three DLBCL patients, one achieved stable disease and two others had progressive disease. Copanlisib was well tolerated [&lt;ulink linkID="1346960" linkType="Reference"&gt;1346960&lt;/ulink&gt;]. In May 2015, results from an exploratory biomarker analysis were presented at the 51st ASCO meeting in Chicago, IL. In the expansion cohort of patients with mixed solid tumors, PTEN protein loss, but not PIK3CA mutations alone, might improve response to copanlisib. Regardless of PTEN or PIK3CA status, patients with NHL, particularly those with follicular lymphoma, had response to copanlisib [&lt;ulink linkID="1661682" linkType="Reference"&gt;1661682&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, a clinical trial application was filed, presumed to be for advanced solid tumor [&lt;ulink linkID="1589794" linkType="Reference"&gt;1589794&lt;/ulink&gt;], [&lt;ulink linkID="1589812" linkType="Reference"&gt;1589812&lt;/ulink&gt;]; in May 2016, review of the application was concluded though the outcome was not published yet [&lt;ulink linkID="1766584" linkType="Reference"&gt;1766584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In December 2017, pooled safety analysis data from four phase I and II studies (NCT00962611; &lt;ulink linkID="193917" linkType="Protocol"&gt;NCT02155582&lt;/ulink&gt;; and NCT01660451 Part A and B) which evaluated the safety of iv copanlisib in patients with relapsed indolent non-Hodgkin’s lymphoma were presented at the 59th ASH Annual Meeting and Exposition in Atlanta, GA. Patients (n = 168) received copanlisib on days 1, 8 and 15 of a 28-day cycle at either 0.8 mg/kg or equivalent dose of 10 mg until disease progression or unacceptable toxicity. Hyperglycemia, diarrhea and hypertension were the most common TEAEs of any grade (10.6, 35.7 and 14.5% of patients, respectively). The most common grade 3 or 4 TEAEs were reported for hyperglycemia, hypertension and neutropenia (31.5, 26.8 and 8.3% of patients, respectively, for grade 3; and 6.0, 0 and 11.3% of patients, respectively, for grade 4) [&lt;ulink linkID="1989051" linkType="Reference"&gt;1989051&lt;/ulink&gt;], [&lt;ulink linkID="1989556" linkType="Reference"&gt;1989556&lt;/ulink&gt;]. In October 2018, data were presented at 2018 ESMO Congress in Munich, Germany. Diarrhea (36/5/0%), fatigue (29/3/0%) and nausea (26/1/0) were the other all-grade/grade 3/grade 4 AEs reported in &amp;gt;25% of patients and serious AEs of interest reported were pneumonia (10/7/1%), pneumonitis (6/3/0%) and one case of grade 4 colitis.  ORR was 60%, with 21 (12%) patients with complete responses (CR; 1 uCR), 79 (47%) with partial responses (PR) and 51 (30%) with stable disease (SD).  ORR, as per investigator assessment, was 54% with 9 (5%) CR, 81 (48%) PR and 54 (32%) SD [&lt;ulink linkID="2084763" linkType="Reference"&gt;2084763&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;​In April 2019, preclinical data were presented at the 2019 AACR Annual Meeting in Atlanta, GA. The combination of &lt;ulink linkID="89138" linkType="Drug"&gt;rogaratinib&lt;/ulink&gt; and copanlisib showed synergistic effects in inhibiting cell proliferation of Hep38, SNU-387 and Huh-7 hepatocellular carcinoma  cells. Rogaratinib monotherapy (24 mg/kg po bid) in hepatocellular carcinoma  patient-derived xenograft (PDX) models showed significantly improved efficacy (TGI = 96%) relative to copanlisib (10 mg/kg iv 2 days on/5 days off; TGI = 39%) or lenvatinib (2 or 5 mg/kd po qd; TGI = 64%); addition of copanlisib to rogaratinib did not improve the already high efficacy. In squamous cell carcinoma of head and neck cell lines with at least one elevated FGFR subtype, rogaratinib demonstrated antiproliferative activity and the combination of rogaratinib with copanlisib showed additive to synergistic effects in CAL33 HNSCC cells. In squamous cell carcinoma of head and neck PDX models treated with rogaratinib (38 mg/kg po bid), copanlisib (10 mg/kg iv 2 days on/5 days off) or &lt;ulink linkID="10388" linkType="Drug"&gt;cetuximab&lt;/ulink&gt; (50 mg/kd iv q7d) as monotherapy or in combination, relative tumor growth rate compared with vehicle control was improved. Rogaratinib plus copanlisib improved responses in cetuximab-resistant and cetuximab-sensitive HNSCC models, and either rogaratinib or copanlisib plus cetuximab showed a trend for improved efficacy [&lt;ulink linkID="2134057" linkType="Reference"&gt;2134057&lt;/ulink&gt;]. Further preclinical data were presented at the same conference. In the JMSU-1 and RT112 cell lines, rogaratinib in combination with copanlisib showed synergistic efficacy for inhibited proliferation and increased apoptosis at relevant clinical concentrations. In vivo, rogaratinib monotherapy induced regression of subcutaneous JMSU-1 tumors with 6 out of 9 mice showing complete response and reduced growth of RT112 tumors, while copanlisib as a single agent was not effective in both models. Rogaratinib in combination with copanlisib was not superior to rogaratinib monotherapy in JMSU-1 model but showed significantly improved antitumor activity in RT-112 model. In UBC models expressing wildtype or hotspot mutated PIK3CA, rogaratinib antitumor activity increased when combined with copanlisib [&lt;ulink linkID="2133992" linkType="Reference"&gt;2133992&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2018, preclinical data were presented at 109th AACR Annual Meeting in Chicago, IL.  In human ABC-DLBCL cell lines, &lt;ulink linkID="110323" linkType="Drug"&gt;BAY-1830839&lt;/ulink&gt; in combination with BTK inhibitor or copanlisib showed synergistic inhibition of NF-kabba B activation and cell viability. In vivo, combination treatment of IRAK4 inhibitor and ibrutinib (a covalent BTK inhibitor) demonstrated synergistic anti-tumor activity with significantly improved efficacy in human ABC-DLBCL xenograft models TMD-8 and OCI-LY10 (MYD88 (mut)/CD79A/B (mut)) relative to monotherapy. Furthermore, BAY-1830839 + copanlisib combination showed a synergistic anti-tumor activity with significant improvement of copanlisib monotherapy efficacy in ABC-DLBCL patient-derived xenograft models [&lt;ulink linkID="2022548" linkType="Reference"&gt;2022548&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2017, preclinical data were presented at the 108th AACR Annual Meeting in Washington DC. Copanlisib had high affinity to PI3Kalpha which translated into potent cellular pathway engagement and apoptosis induction in tumor cells. In PIK3CA-driven KPL4 breast tumor cells, pathway engagement of p-AKT and p-PRAS40 in a dose- and time-dependent manner was observed at &amp;gt;/= 72 h. In vivo, approximately 100-fold higher copanlisib levels were observed in the tumor when compared with plasma at 48 h, with a much slower drug clearance from the tumor than from plasma [&lt;ulink linkID="1913775" linkType="Reference"&gt;1913775&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2016, preclinical data were presented at the 39th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. In two cell line xenograft models of ER+ breast cancer, MCF7 (PIK3CA-E545K) and ZR751(PIK3CA WT), copanlisib induced significant tumor growth inhibition as single agent compared with vehicle control. Copanlisib in combination with hormonal blockade by either &lt;ulink linkID="44314" linkType="Drug"&gt;tamoxifen&lt;/ulink&gt; or &lt;ulink linkID="3313" linkType="Drug"&gt;fulvestrant&lt;/ulink&gt; showed modest increase in anti-tumor activity. However, triple combinations of copanlisib + &lt;ulink linkID="10271" linkType="Drug"&gt;palbociclib&lt;/ulink&gt; + tamoxifen and copanlisib + palbociclib + fulvestrant, exhibited robust tumor regressions. Additionally, a statistically significant improvement in anti-tumor activity was observed with these triple combinations when compared with standard of care combination of palbociclib plus fulvestrant [&lt;ulink linkID="1885312" linkType="Reference"&gt;1885312&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In December 2016, preclinical data were presented at the 58th ASH Annual Meeting and Exposition in San Diego, CA. Copanlisib demonstrated antitumor activity in a wide range of cell lines with a median IC50 value of 22, 36, 22 and 23 nM against all the cell lines, MZL cells, MCL cells and CLL MEC1 cells, respectively. Among 17 cell lines tested, different copanlisib-containing combinations exerted synergistic or additive effects: 88, 82, 76, 71, 65, 59, 53, 47, 35 and 12% of cell lines in which combinations were beneficial with copanlisib + MI-2, copanlisib + ibrutinib, copanlisib + panobinostat, copanlisib + lenalidomide, copanlisib + rituximab, copanlisib + romidepsin, copanlisib +  roniciclib, copanlisib + bortezomib, copanlisib + bendamustine and copanlisib + ruxolitinib, respectively [&lt;ulink linkID="1881633" linkType="Reference"&gt;1881633&lt;/ulink&gt;]. At the same conference, further preclinical data were presented. In an ibrutinib-resistant MyD88-mutant-LY0257 patient-derived activated B-cell-diffuse large B-cell lymphoma (ABC-DLBCL) model, copanlisib treatment resulted in complete tumor regression. In CD79b-mutant-TMD-8 cell line and Ly2298 patient-derived ABC-DLBCL models, ibrutinib + copanlisib intermittent iv treatment was well tolerated and produced complete tumor regression [&lt;ulink linkID="1881866" linkType="Reference"&gt;1881866&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2015, preclinical data were presented at the 20th EHA Congress in Vienna, Austria. In MCL cell lines and Jurkat cell lines, treatment with copanlisib (5 microM) significantly decreased the cell growth and at 72 h,  significantly stronger reduction in cell growth was observed when compared with untreated control group, while treatment with A-66, TGX-221 and &lt;ulink linkID="48319" linkType="Drug"&gt;idelalisib&lt;/ulink&gt; showed much slighter effects [&lt;ulink linkID="1669232" linkType="Reference"&gt;1669232&lt;/ulink&gt;].  In May 2016, similar preclinical data were presented at Kinase 2016 in Nottingham, UK [&lt;ulink linkID="1764475" linkType="Reference"&gt;1764475&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA.     Copanlisib inhibited 9 out of 23 gastric cancer cells with IC50 values below 1 microM and reduced the tumor volume  in  various gastric cancer xenograft models [&lt;ulink linkID="1649577" linkType="Reference"&gt;1649577&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, data were presented at the 24th EORTC-NCI-AACR symposium in Dublin, Ireland. The AKT-dependent feedback suppression of receptor tyrosine kinase expression was relieved by both copanlisib and&lt;ulink linkID="60210" linkType="Drug"&gt; MK-2206&lt;/ulink&gt; to nearly similar levels in breast cancer models. The inhibition of the PI3K-dependent signaling intermediates was more effective with copanlisib; however, the degree of inhibition of AKT substrates was nearly similar  [&lt;ulink linkID="1336587" linkType="Reference"&gt;1336587&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, data from studies performed in biliary tract cancer (BTC) models were presented at the 103rd AACR meeting in Chicago, IL. In vitro, strong synergistic antiproliferative activity was seen with copanlisib and &lt;ulink linkID="56559" linkType="Drug"&gt;refametinib&lt;/ulink&gt; combination. In vivo, copanlisib and refametinib combinations showed additive to synergistic effect in a range of xenograft models, including a tumor response rate of 71.4% in the combination group compared with 0% in the monotherapy group. The synergistic activity was indicated to be mediated by the upregulation of pro-apoptotic Bim (thereby apoptosis induction). In EGI-1 xenograft in vivo model, copanlisib in combination with gemcitabine or &lt;ulink linkID="54624" linkType="Drug"&gt;regorafenib&lt;/ulink&gt; showed strong synergistic antitumor activity. Copanlisib, gemcitabine and regorafenib monotherapies showed moderate antitumor activity against EGI-1 KRAS mutant BTC model. No induction of PARP cleavage an	d Bim expression was seen with copanlisib and refametinib alone [&lt;ulink linkID="1275179" linkType="Reference"&gt;1275179&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at the 102nd AACR meeting in Orlando,FL. Copanlisib was found to be active in  sensitive human breast  cancer (BC) cell lines (IC50 &amp;lt; 50) considered as HER2-positive and/or with PIK3CA-activating mutations. Copanlisib showed antiproliferative activity in PIK3CA (mut) and HER2-/ HER3-positive BC cell lines. The induction of apoptosis by copanlisib was implicated from the immediate reduction of the cancer incidence (&amp;lt; 1) post-treatment in PIK3CA (mut) (BT-20, BT-474) and PTEN (null) (ZR-75-1) cells, which was further confirmed by PARP cleavage. The apoptotic activity of copanlisib was restored in B-cell lymphoma (Bcl)-2-expressing PIK3CA (mut) BC cell line T47D in combination with ABT-737. The MDA-MB-468 BC cell line was sensitized to apoptosis by copanlisib on inhibition of mTORC1and/or mTORC2 by rapamycin and shRNA knockdown of rictor, respectively [&lt;ulink linkID="1176786" linkType="Reference"&gt;1176786&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2010, preclinical data were presented at the 22nd EORTC-NCI-AACR Symposium in Berlin, Germany, showing that  copanlisib had IC50 values of 0.5, 3.7, 6.4 and 0.7 nM for its activity against PI3K alpha, beta, gamma and delta, respectively, and 45 nM for its activity against mTOR [&lt;ulink linkID="1145955" linkType="Reference"&gt;1145955&lt;/ulink&gt;]. Data were also presented at this conference showing that copanlisib in combination with &lt;ulink linkID="56559" linkType="Drug"&gt;BAY-869766&lt;/ulink&gt; demonstrated efficacy in several murine colorectal cancer xenograft models [&lt;ulink linkID="1144250" linkType="Reference"&gt;1144250&lt;/ulink&gt;], and synergy in NSCLC cell lines with various genetic alterations found in patients [&lt;ulink linkID="1144223" linkType="Reference"&gt;1144223&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, preclinical data were presented at the 101st AACR meeting in Washington DC. Copanlisib potently blocked cell proliferation in tumor cell lines tested with IC50 values ranging from 1 to 100 nM [&lt;ulink linkID="1089513" linkType="Reference"&gt;1089513&lt;/ulink&gt;]. Also at the meeting, copanlisib was demonstrated to induce tumor regression and tumor stasis in several animal models of  breast, colorectal and non-small-cell lung cancers and the drug was synergistic with paclitaxel in the Lu7860 patient-derived NSCLC mice xenograft model [&lt;ulink linkID="1089515" linkType="Reference"&gt;1089515&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2016, the EMA's Pediatric Committee adopted a positive opinion on pediatric investigation plan (PIP) for copanlisib in the treatment of advanced solid tumors [&lt;ulink linkID="1793043" linkType="Reference"&gt;1793043&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2017-10-26T00:00:00.000Z</StatusDate><Source id="1975885" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-01-08T00:00:00.000Z</StatusDate><Source id="1755605" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-08-03T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate>2016-06-28T00:00:00.000Z</StatusDate><Source id="1906962" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2018-02-02T00:00:00.000Z</StatusDate><Source id="1900871" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2726">Neuroblastoma</Indication><StatusDate>2018-04-30T00:00:00.000Z</StatusDate><Source id="2042712" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1772">Osteosarcoma</Indication><StatusDate>2018-04-30T00:00:00.000Z</StatusDate><Source id="2042712" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2975">Ewing sarcoma</Indication><StatusDate>2018-04-30T00:00:00.000Z</StatusDate><Source id="2042712" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2017-08-02T00:00:00.000Z</StatusDate><Source id="1925083" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="311">T-cell lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2448">Rhabdomyosarcoma</Indication><StatusDate>2018-04-30T00:00:00.000Z</StatusDate><Source id="2042712" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1734">Chronic lymphocytic leukemia</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2033296" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2033296" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2018-07-25T00:00:00.000Z</StatusDate><Source id="2033296" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1747">Splenic marginal zone lymphoma</Indication><StatusDate>2017-02-07T00:00:00.000Z</StatusDate><Source id="1899225" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate><Source id="2031285" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate><Source id="2031285" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2017-01-31T00:00:00.000Z</StatusDate><Source id="1955280" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="X2">Asia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate><Source id="2031285" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate><Source id="2031285" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate><Source id="2031285" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2016-11-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2016-03-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-01-12T00:00:00.000Z</StatusDate><Source id="978349" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2010-04-01T00:00:00.000Z</StatusDate><Source id="1035881" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2013-04-07T00:00:00.000Z</StatusDate><Source id="1399927" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2011-12-12T00:00:00.000Z</StatusDate><Source id="1237047" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2017-04-27T00:00:00.000Z</StatusDate><Source id="1922811" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2017-04-27T00:00:00.000Z</StatusDate><Source id="1922811" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2017-09-14T00:00:00.000Z</StatusDate><Source id="1962389" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-05-12T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="X2">Asia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2015-05-19T00:00:00.000Z</StatusDate><Source id="1650369" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2015-05-19T00:00:00.000Z</StatusDate><Source id="1650369" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2015-05-19T00:00:00.000Z</StatusDate><Source id="1650369" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2015-09-28T00:00:00.000Z</StatusDate><Source id="1955280" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1753">Peripheral T-cell lymphoma</Indication><StatusDate>2017-02-10T00:00:00.000Z</StatusDate><Source id="1900871" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3658">Metastatic colorectal cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2018-10-16T00:00:00.000Z</StatusDate><Source id="2093622" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2018-05-08T00:00:00.000Z</StatusDate><Source id="2033296" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2014-09-01T00:00:00.000Z</StatusDate><Source id="1589812" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="SA">Saudi Arabia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2015-05-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2012-11-22T00:00:00.000Z</StatusDate><Source id="1327182" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14455">Bayer AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1746">Marginal zone B-cell lymphoma</Indication><StatusDate>2017-02-07T00:00:00.000Z</StatusDate><Source id="1899227" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="US">US</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of relapsed follicular lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-09-14T00:00:00.000Z</MileStoneDate><Source id="1962389" type="PR"/></Row><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="US">US</Country><Indication id="1746">Marginal zone B-cell lymphoma</Indication><AwardedIndication>Treatment of adult patients with relapsed marginal zone lymphoma who have received at least two prior therapies </AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2019-05-29T00:00:00.000Z</MileStoneDate><Source id="2156883" type="PR"/></Row><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="US">US</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of relapsed or refractory follicular lymphoma (FL)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-05-17T00:00:00.000Z</MileStoneDate><Source id="1928196" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="EU">EU</Country><Indication id="1746">Marginal zone B-cell lymphoma</Indication><AwardedIndication>Treatment of marginal zone lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-08-24T00:00:00.000Z</MileStoneDate><Source id="2079561" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="EU">EU</Country><Indication id="1746">Marginal zone B-cell lymphoma</Indication><AwardedIndication>Treatment of marginal zone lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2018-07-19T00:00:00.000Z</MileStoneDate><Source id="2059302" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="US">US</Country><Indication id="1746">Marginal zone B-cell lymphoma</Indication><AwardedIndication>Treatment of nodal marginal zone lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-07-02T00:00:00.000Z</MileStoneDate><Source id="1899229" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="US">US</Country><Indication id="1747">Splenic marginal zone lymphoma</Indication><AwardedIndication>Treatment of splenic marginal zone lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-02-07T00:00:00.000Z</MileStoneDate><Source id="1899225" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="US">US</Country><Indication id="1746">Marginal zone B-cell lymphoma</Indication><AwardedIndication>Treatment of extranodal marginal zone lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-02-07T00:00:00.000Z</MileStoneDate><Source id="1899227" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="US">US</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of follicular lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2015-02-05T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="11">Priority Review</RegulatoryDesignation><OwnerCompany id="14455">Bayer AG</OwnerCompany><Country id="US">US</Country><Indication id="1745">Follicle center lymphoma</Indication><AwardedIndication>Treatment of relapsed or refractory follicular lymphoma (FL)</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2017-05-17T00:00:00.000Z</MileStoneDate><Source id="1928196" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01553"><Name>Phosphoinositide 3-kinase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14455">Bayer AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29603">H Lee Moffitt Cancer Center and Research Institute</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5</Smiles><Smiles>COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5.Cl.Cl</Smiles></StructureSmiles><Deals><Deal id="237317" title="H. Lee Moffitt Cancer Center and Research Institute to conduct phase II study of Bayer's copanlisib for cholangiocarcinoma "/></Deals><PatentFamilies><PatentFamily id="1851318" number="WO-2010034414" title="Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma"/><PatentFamily id="1852658" number="WO-2011128407" title="Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations"/><PatentFamily id="1954669" number="WO-2004029055" title="Fused azole-pyrimidine derivatives"/><PatentFamily id="2215746" number="WO-2008070150" title="Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis"/><PatentFamily id="2304434" number="WO-2012136553" title="Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts"/><PatentFamily id="2813251" number="WO-2014166820" title="Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas"/><PatentFamily id="2952213" number="WO-2015082322" title="Combination of PI3K-inhibitors"/><PatentFamily id="3359993" number="WO-2016142312" title="Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations"/><PatentFamily id="3359994" number="WO-2016142313" title="Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines"/><PatentFamily id="3749460" number="WO-2017134000" title="Copanlisib biomarkers"/><PatentFamily id="3749461" number="WO-2017134030" title="Copanlisib Biomarkers"/><PatentFamily id="3795212" number="WO-2017157792" title="Combinations of copanlisib"/><PatentFamily id="3996656" number="WO-2018054782" title="Combination of PI3K-inhibitors"/><PatentFamily id="4171322" number="WO-2018153980" title="Combinations of copanlisib with anti-PD-1 antibody"/><PatentFamily id="4286147" number="WO-2018215282" title="Combination of Bub1 and PI3K inhibitors"/><PatentFamily id="4328341" number="WO-2019002068" title="Combination of a PI3K-inhibitor with an androgen receptor antagonist"/><PatentFamily id="4429001" number="WO-2019048527" title="Formulations of copanlisib"/><PatentFamily id="4537310" number="WO-2019105734" title="Combinations of copanlisib"/><PatentFamily id="4537323" number="WO-2019105835" title="Combinations of copanlisib and anetumab ravtansine"/><PatentFamily id="515966" number="EP-02168582" title="Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines"/><PatentFamily id="83954" number="WO-2012136549" title="Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>12</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>6</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bayer AG" id="14455"/><CountAsOwner>21</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>21</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Namyang Aloe Co Ltd" id="22261"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></drugRecordOutput>